AIM Vaccine Co., Ltd. Class H (HK:6660) has released an update.
AIM Vaccine Co., Ltd. has submitted an application for clinical trials of its innovative human diploid rabies vaccine to the Chinese authorities. This new vaccine aims to overcome technical challenges of previous versions, offering improved safety and flexibility in administration methods. As a major rabies vaccine supplier, AIM Vaccine is poised to enhanceglobal marketofferings with this breakthrough.
For further insights into HK:6660 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ZGD, HGGG: 2 Gold ETFs with More than 20% Expected Returns, According to Analysts
- Immunic Reports Q3 Earnings and Provides Corporate Update
- Icahn to Boost Stake in CVR Energy to 81% by Cutting IEP’s Dividend
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
